The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a ‘Pick a Winner’ design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62–86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

[1]  Robert K Hills,et al.  Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. , 2011, Blood.

[2]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[3]  W. Jędrzejczak,et al.  A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. , 2007, Blood.

[4]  A. Cox,et al.  Geranylgeranyltransferase I as a target for anti-cancer drugs. , 2007, The Journal of clinical investigation.

[5]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[6]  P. Greenberg,et al.  A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. , 2007, Blood.

[7]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[8]  W. R. Bishop,et al.  Lipid posttranslational modifications. Farnesyl transferase inhibitors. , 2006, Journal of lipid research.

[9]  W. Scheithauer,et al.  Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hao Wang,et al.  Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Channing J Der,et al.  Farnesyltransferase inhibitors: promises and realities. , 2002, Current opinion in pharmacology.

[12]  G. Prendergast,et al.  Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. , 2002, Cancer research.

[13]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[14]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.